|Bid||31.55 x 200|
|Ask||31.89 x 700|
|Day's Range||30.25 - 33.13|
|52 Week Range||11.30 - 44.50|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2018 - May 11, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||51.57|
Arena (ARNA) reports narrower-than-expected Q4 loss. However, revenues decrease year over year. The company is likely to advance ralinepag in phase III study in the second half of 2018.
Arena (ARNA) posted narrower-than-expected loss in the fourth quarter of 2017. However, revenues decreased significantly year over year.
- Etrasimod Phase 2 Data in UC Anticipated this Month - Ralinepag Phase 3 Clinical Program Expected to Begin in H2 2018 SAN DIEGO , March 14, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ...
Don't be caught off-guard: Arena Pharmaceuticals (NASDAQ: ARNA ) releases its next round of earnings Tuesday. Want to skip the homework and get all the facts in one place? We thought so. Here is your everything-that-matters ...
In 2017, Novo Nordisk’s (NVO) Saxenda sales reached 2.6 billion Danish kroner, a YoY (year-over-year) rise of 64% in local currencies. According to IQVIA, by the end of November 2017, Saxenda accounted for 79%, 86%, 72%, 52%, 47%, 40%, 30%, 19%, 14%, and 6% of the total value of anti-obesity medications sold in the United Arab Emirates, Canada, Denmark, the United States, Italy, Spain, Brazil, Germany, Australia, and Mexico, respectively. In December 2017, Novo Nordisk submitted an application to the FDA seeking an update to Saxenda’s label to include data from the LEADER trial.
SAN DIEGO , March 8, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), will announce its fourth quarter and full-year 2017 financial results on Wednesday, March 14, 2018 , before the open ...
Although Arena's (ARNA) only approved product, Belviq, has an unimpressive show so far, the company's efforts to improve the drug's performance might drive the stock in Q4.
SAN DIEGO, March 1, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA), will present Phase 1 and preclinical data for the investigative drug candidate APD371 at the American Pain Society (APS) Annual Scientific Meeting on March 6. APD371 was evaluated in Phase 1 studies to assess the safety, tolerability and pharmacokinetics of a single ascending dose (SAD) or multiple ascending doses (MAD) in healthy volunteers.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) stock ...
It’s no secret that hedge funds have been underperforming the market by quite a wide margin in the last couple of years. However, in the industry that encompasses hundred of hedge funds and has gathered over $3.0 trillion in assets under management, there still are many players that posted great returns. This is particularly the […]
"We appreciate the dedication, support and contributions of Scott, Phil and Christine in helping us to build a strong foundation," added Amit D. Munshi, President and CEO of Arena. Arena Pharmaceuticals is focused on developing novel, small molecule drugs with optimized receptor pharmacology and pharmacokinetics designed to deliver broad clinical utility across several therapeutic areas.
NEW YORK, NY / ACCESSWIRE / February 9, 2018 / U.S. markets continued to plunge alongside rising interest rates on Thursday. The Dow Jones Industrial Average dropped 4.15 percent to close at 23,860.46, ...
SAN DIEGO, Feb. 6, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA), today announced that that members of its senior management team will present at two upcoming investor conferences in New York City. A live audio webcast of the presentations will be available under the investor relations section of Arena's website at www.arenapharm.com. To learn more about Arena's clinical programs, development plans and upcoming milestones for 2018, a video interview with CEO Amit Munshi is available under the Events and Presentations section of Arena's website at www.arenapharm.com.
Arena Pharmaceuticals Inc (NASDAQ:ARNA), a $1.47B small-cap, operates in the healthcare industry, which has experienced tailwinds from issues such as higher demand driven by an aging population and the increasingRead More...
NEW YORK, Jan. 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Alliqua ...
SAN DIEGO, Jan. 22, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA), today announced that it will host a key opinion leader (KOL) event for investors focused on sphingosine-1-phosphate (S1P) receptor modulation in the treatment of autoimmune diseases in New York City on Monday, January 29, from 12-1:30 p.m. EST. The meeting will feature presentations by KOLs, Jerold Chun, M.D., Ph.D., Professor and Senior Vice President of Neuroscience Drug Discovery at Sanford Burnham Prebys Medical Discovery Institute (SBP), and Eric Gershwin, M.D., Distinguished Professor of Medicine, as well as the Jack and Donald Chia Professor of Medicine, and Chief of the Division of Allergy and Clinical Immunology at the University of California Davis School of Medicine.
We hear from executives from Alnylam, Arena Pharmaceuticals, and Spark Therapeutics at the biggest healthcare conference of the year.
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) received an upgrade from Wall Street on Wednesday as it awaits Phase 2 data for the S1P modulator etrasimod in ulcerative colitis. The Analyst Wells Fargo's ...
Shares of MoneyGram (MGI) are tanking, down 9%, after US regulators blocked the sale of the money transfer company to Alibaba’s (BABA) Ant Financial Services. The $1.2 billion deal, which was in the works for several years, would have helped Alibaba solidify its US financial presence. Southwest Airlines (LUV) announced it will share its tax cut windfall with workers.
SAN DIEGO , Dec. 21, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, will present a corporate ...
Assessing Arena Pharmaceuticals Inc’s (NASDAQ:ARNA) performance as a company requires looking at more than just a years’ earnings data. Below, I will run you through a simple sense check toRead More...